Sign In

Richard Baum

ONDCP, Senior Policy Analyst, Emerging Threats

Professional Background

Richard J. Baum is a distinguished public policy expert and long-time advocate in the field of drug policy. With an impressive career spanning over three decades, Baum has made significant contributions to combating drug addiction and reforming drug policies in the United States. He served as the Acting Director of the White House Office of National Drug Control Policy (ONDCP) from March 2017 to February 2018, where he played a crucial role in addressing the national opioid crisis. His dedication to aiding communities affected by substance abuse is evident through his concurrent role as the Executive Director of the bipartisan Commission on Combating Drug Addiction and the Opioid Crisis.

Baum's journey in drug policy began as a Congressional Committee staffer at the House Select Committee on Narcotics from 1988 to 1993. This experience laid the foundation for his in-depth understanding of the intricate interplay between drug policy, law enforcement, and public health. His notable tenure of over 24 years at ONDCP has seen him assume various impactful positions, including Senior Policy Analyst and Senior Policy Advisor. In his current role at the Office of Performance and Budget, Baum is responsible for the strategic development of the 2022 National Drug Control Strategy, focusing on critical issues such as low threshold treatment engagement, harm reduction, and promoting collaboration between health and justice systems.

In addition to his government service, Richard Baum brings his expertise into academia as an Adjunct Professor of Public Policy at Georgetown University's McCourt Graduate School. Each Spring semester, he teaches a thoughtfully designed course entitled: "The War on Drugs: Causes, Consequences, and Alternatives." This position underlines his commitment to not only shaping policy but also educating the next generation of leaders in public policy.

Education and Achievements

Baum's educational background is as robust as his professional experience. He earned a Bachelor of Arts (B.A.) in Government, International Affairs, and Public Policy from Georgetown University. To further his expertise, he obtained a Master's in Public Administration (M.P.A.) from the University of Colorado Denver and a Master's in National Security Studies from Georgetown University. This diverse academic foundation has equipped him with a comprehensive understanding of both domestic and international policy issues.

Richard Baum’s evolution in drug policy continues to be shaped by his academic knowledge and practical experience. His work has contributed to opening dialogues on substance use disorder and progressing towards more humane and effective approaches to drug legislation. He has advocated for significant reforms aimed at reducing the stigma associated with addiction while promoting vital prevention strategies.

Achievements

Baum’s career is marked by a series of notable achievements important not only to drug policy but also to public health. His leadership at ONDCP and his role in the development of critical national strategies to address drug addiction exemplify his commitment to facilitating collaborative efforts within federal, state, and local agencies.

His work on the bipartisan Commission was especially instrumental during a time when addiction rates were escalating, emphasizing the need for comprehensive solutions that encompass treatment, prevention, and justice reform. The collaborative nature of this initiative helped unify diverse stakeholders, including community organizations, healthcare providers, and law enforcement, in their efforts to combat this pressing crisis.

Moreover, Baum’s role as the Coordinator of U.S. Anti-Doping Policy in sports reflects his expertise in addressing the challenges of substance use within competitive sports environments. By promoting fair play and integrity, he aims to influence policy in a way that balances the health of athletes with the demands of competitive integrity.

Outside of his professional pursuits, Richard Baum resides in Falls Church, Virginia, with his wife Linda Bloss-Baum, and their two children, Alexandra and Matthew, further enriching his understanding of community and family dynamics. The incorporation of personal experience into his work adds depth to his advocacy, illustrating the importance of connection and compassion in policy-making. Underneath his professional accolades lies an underlying passion for public service and community welfare.

Questions About Richard J. Baum

  1. How did Richard J. Baum's early experiences in the House Select Committee influence his passionate advocacy for drug policy reform?

  2. In what ways has Richard J. Baum’s role at the ONDCP shaped the national conversation on drug addiction and public health?

  3. What insights can Richard J. Baum provide to students about the complexities of drug policy in his Georgetown University

Highlights

Mar 16 · linkedin

“The opioid epidemic’s rising mortality rate among Black and, more recently, Hispanic people in the Northeast, follows a shift in drug use from a market driven by prescription opioids to one dominated by illicit fentanyl, according to a study published in the June 2023 issue of the scientific journal Addiction.

But the focus on fentanyl as the “killer” misses the point, said Joseph Friedman, an addiction researcher at UCLA and the study’s author. For years, hospitals have safely used medical grade fentanyl for surgical pain because the potency is strictly regulated. “It's not the strength of fentanyl, that's risky,’’ he said. “It's the fact that the potency fluctuates wildly in the illicit market.”

Studies of street drugs, he said, show that in illicit drugs the potency can vary from one percent to 70% fentanyl.

“Imagine ordering a mixed drink in a bar and it contains one to 70 shots,’’ Friedman said, “and the only way you know is to start drinking it…There would be a huge number of alcohol overdose deaths.’’

Jan 6 · linkedin

“The omnibus bill encompasses many of the proposals that lawmakers — especially those on the Senate Finance Committee — have championed all year.

A major reform is the elimination of the additional waiver physicians are required to get from the Drug Enforcement Administration (DEA) to prescribe buprenorphine. In effect, the bill nixes this waiver and requires all providers to get additional training on how to recognize and treat addiction.

The bill was championed during the year as the Mainstreaming Addiction Treatment (MAT) Act. It is hoped to eliminate administrative hurdles, stigma and access hurdles to the drug.

And even though 2023 will see the arrival of a divided government, with Republicans reclaiming a majority in the House of Representatives, Washington observers point out that behavioral health initiatives enjoy broad bipartisan support. One bill folded into the omnibus bill, the Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R. 7666), passed the House on a strong bipartisan vote. This leaves the door open for additional action in 2023.

The passage of the omnibus bill portends well for those efforts.”

Richard Baum
Add to my network

Location

Washington DC-Baltimore Area